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ABSTRACT 
Primary hyperparathyroidism (PHPT) is a common endocrine disorder characterized by 
abnormally excessive secretion of parathyroid hormone (PTH) and elevated serum 
calcium. PHPT patients can develop a wide range of complications affecting many 
body organs such as the skeleton, kidneys and heart. In the majority of patients, PHPT 
is due to a solitary adenoma and less frequently due to multiglandular disease. Very 
rarely PHPT is caused by a parathyroid carcinoma. 
This thesis aimed at a better understanding of the genetic as well as epigenetic 
mechanisms involved in this disease in order to improve future patients management. 
In study I we have investigated large parathyroid adenomas (≥ 4 grams) and detected 
frequent MEN1, but rare HRPT2/CDC73 mutations and low MIB1 proliferation index. 
The majority of the tumors had loss of parafibromin expression and positive APC 
expression. Furthermore, gain of chromosome 5 was the most unique and frequent copy 
number alteration detected in this group, while very rarely detected in unselected 
adenomas. We concluded that a subset of large parathyroid adenomas have distinct 
genetic profile and pronounced clinical features reflected by significantly higher serum 
calcium.  
In study II we examined the role of constitutional APC mutations in parathyroid 
tumors from two patients with APC mutation-associated familial colorectal cancers. 
Pathological revision confirmed the benign nature of both tumors. None of them had 
somatic mutations or DNA copy number alterations of the APC gene and both tumors 
displayed strong APC and parafibromin expression with low MIB index. Although the 
APC 1A promoter was hypermethylated, promoter APC 1B was unmethylated and this 
was consistent with normal APC mRNA expression. Our results supported the benign 
nature of the parathyroid tumors and excluded a possible association between 
constitutional APC mutations and parathyroid tumorigenesis. 
In study III we defined the molecular cytogenetic profile of CDC73/HRPT2-mutated 
parathyroid tumors. All the carcinomas displayed frequent DNA copy number losses on 
chromosome 1p and 13 while the adenomas did not display any significant alterations. 
All the carcinomas were diploid at the CDC73 gene locus, but three adenomas had loss 
at this locus. The CDC73 promoter was unmethylated in all the tumors. The carcinomas 
displayed more loss of heterozygosity (LOH) events than the adenomas, and two 
carcinomas had LOH at the CDC73 locus. These results suggest that CDC73-mutated 
parathyroid adenomas exhibit a partly unique cytogenetic profile in addition to that of 
carcinomas and unselected adenomas. 
In study IV analyses of promoter methylation status in a panel of benign and malignant 
parathyroid tumors revealed frequent hypermethylation of APC 1A, β-catenin and 
RASSF1A promoters in the adenomas which correlated with reduced mRNA 
expression. Parathyroid carcinomas were hypermethylated for APC 1A and exclusively 
for SFRP1. No changes in global methylation could be detected and tumor groups with 
known MEN1 or CDC73 mutations did not display different methylation profile. We 
concluded that aberrant promoter methylation of APC 1A, β-catenin, RASSF1A and 
SFRP1 can play a role in parathyroid tumorigenesis and hypermethylation of SFRP1 
can act as a potential epigenetic marker for parathyroid carcinomas. 
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INTRODUCTION 
 
DISCOVERY OF PARATHYROID GLANDS  
 
The parathyroid gland is the last major organ identified and described in the human 
body [1]. This could be attributed to the anatomical position as well as the small size of 
these glands. Parathyroid glands were first observed by Richard Owen in 1850, 
however, Owen did not make any description of the nature of these glands and did not 
even name them. In his published article in Transactions in 1852, Owen described the 
glands as “small compact yellow glandular body attached to the thyroid to the point 
where the vein merges” [2]. Following Owen, the surgeon Robert Remark and the 
pathologist Rudolf Virchow have observed the glands, but again they did not make any 
descriptions apart from naming the anatomical location. It was not until 1852 when the 
medical student Ivar Sandström (Figure 1) from Uppsala University in Sweden made 
the first detailed description of the parathyroid glands and named them as “Glandulae 
Parathyroideae” [3]. 
 
                                 
      Figure 1. Ivar Victor Sandström (1852-1889). 
 
Ivar described the origin of the parathyroid glands as undeveloped embryonic remnants 
from the thyroid glands. His discovery was later published in the local journal Uppsala 
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Läkareförenings Förhandlingar [4]. Being parathyroid glands the last organs 
discovered, the recognition of parathyroid disease came late in 1908 when  
WG MacCallum and Carl Voegtlin attributed symptoms previously linked to the 
thyroid gland to the pathology of parathyroid glands [5]. Thereafter, signs and 
symptoms of parathyroid diseases were gradually recognized. 
 
EMBRYOLOGY AND ANATOMY OF THE PARATHYROID GLANDS 
 
Parathyroid glands develop during the fourth week of gestation. They originate from 
the third and the fourth pharyngeal pouches of the endoderm. They are usually four in 
number, two superior and two inferior and are situated in the anterior aspect of the neck 
just behind the thyroid gland (Figure 2). Supernumerary glands are not uncommon and 
have been reported in about 13% of cases [6]. Parathyroid glands are oval shaped, light 
yellow to reddish brown in color and are small in size with an average weight of 40 to 
60 mg [7, 8]. The inferior glands have a common origin with the thymus, as they are 
both derived from the third pharyngeal pouch. They start to migrate together with the 
thymus inferiorly and medially in the neck and get separated from the thymus just 
before the thymus localizes into the anterior mediastinum [9]. 
 
 
Figure 2. Locations of the parathyroid glands in the neck (posterior view). Modified 
from reference [9]. 
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The superior glands have a shorter migration path in the neck. They arise from the 
fourth pharyngeal pouch and migrate with the thyroid. They localize to the posterior 
mid-portion of the thyroid lobe [10]. The blood supply for the superior and the inferior 
parathyroid glands primarily comes from the inferior thyroid artery [11]. 
 
Ectopic localization of the parathyroid glands and especially the inferior glands are not 
uncommon [12]. This variation in the anatomical location can be simply explained by 
their origin and migration path in the neck. They can be found anywhere between the 
angle of the mandible and the upper mediastinum. In about 5% of the ectopic cases, the 
inferior parathyroid glands are found in the anterior mediastinum [9]. As the superior 
glands have a much shorter migration path in the neck, they are very seldom found at 
ectopic sites in the neck. 
 
HISTOLOGY OF NORMAL PARATHYROID GLANDS 
 
Parathyroid gland tissue is surrounded by a thin connective tissue capsule and consists 
mainly of two cell types, chief and oxyphil cells [10]. Chief cells are small polygonal 
cells with a rounded centrally located nucleus and a weak acidophilic cytoplasm and 
they are the predominant cell type (Figure 3A). In contrast, oxyphil cells are much less 
abundant, rounded, and larger in size and have more intense acidophilic cytoplasm.  
 
While the main function of chief cells is to secrete parathyroid hormone (PTH), the 
function of the oxyphil cells is still unknown. However, oxyphil cells are proposed to 
secrete PTH in chronic kidney diseases (CKDs) [13]. Chief cells stain positive for PTH, 
glycogen, cytokeratin and chromogranin A [14, 15]. In addition to chief and oxyphil 
cells, the parathyroid gland also contains adipocytes. While the number of chief cells 
decreases by age, the number of oxyphil cells and adipocytes increases in number 
during adulthood and adipocytes may constitute up to 50% of the cells in older people. 
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Figure 3. (A) Normal parathyroid gland. (B) Parathyroid adenoma with normal rim. 
(C) Parathyroid carcinoma. (D) Atypical parathyroid adenoma. 
 
FUNCTIONS OF THE PARATHYROID GLANDS 
 
The endocrine function of the parathyroid glands is primarily calcium homeostasis 
(regulation of extracellular calcium level) through the secretion of PTH. The 
extracellular calcium is regarded as the main determinant of PTH secretion and 
parathyroid glands are very sensitive to even slight variations in baseline ionized serum 
calcium (S-Ca2+) levels. PTH secretion has an inverse sigmoidal relationship with  
S-Ca2+ level and the midpoint between minimal and maximal PTH secretion is the set 
point of calcium which changes in parathyroid diseases (Figure 4) [16]. Similar to other 
endocrine organs, parathyroid glands lack ducts and they release PTH directly into the 
blood stream. PTH regulates S-Ca2+ mainly through its action on three major organs, 
namely the kidneys, skeleton and the small intestine (Figure 5). Any drops in the 
normal level of S-Ca2+ will be sensed by the calcium sensing receptor (CASR) 
expressed on parathyroid cell surface [17]. This will lead to downstream signaling and 
activation of the parathyroid glands to secrete or increase PTH secretion into the blood 
stream. PTH acts via the kidneys by enhancing calcium resorption from the distal 
tubules and reducing phosphate absorption from the proximal tubules [18].  
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In addition, PTH enhances the conversion of the inactive form of vitamin D  
(25-hydroxyvitamin D) to the active metabolite, 1, 25-dihydroxyvitamin D-3 via the 
activation of 1α-hydroxylase enzyme in the proximal tubules of the kidney. The active 
form of vitamin D in turn acts on the small intestine to increase intestinal absorption of 
calcium. The effect of PTH on skeleton is mainly through the induction of bone 
resorption which leads to increased release of calcium into the blood stream and causes 
immediate elevation of the extracellular calcium. The net effect of secreted PTH on 
kidneys, bones and the small intestine is increase in the S-Ca2+ level which will be 
perceived by the parathyroid glands through the CASR as a negative feedback signal to 
reduce PTH secretion to a level keeping S-Ca2+ within the normal physiological level. 
 
 
Figure 4. Illustration of the sigmoidal relationship between PTH release and level of  
                 S-Ca2+. 
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Figure 5. Calcium homeostasis. Regulation of extracellular calcium by PTH. 
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DISEASES OF THE PARATHYROID GLANDS – HYPERPARATHYROIDISM 
 
Hyperparathyroidism is a disorder of increased parathyroid gland activity characterized 
by abnormally increased secretion of PTH and elevation of S-Ca2+. The PTH-calcium 
sigmoidal curve is shifted to the right and the calcium set point is increased (Figure 4). 
Based on the underlying pathology of hyperparathyroidism the parathyroid hyperactive 
state is classified into three different types: primary, secondary and tertiary 
hyperparathyroidism [19]. 
 
Primary hyperparathyroidism (PHPT) 
 
PHPT is defined as excessive production of PTH by the parathyroid glands due to 
disorders arising from within the glands themselves and causing abnormally high  
S-Ca2+ [19]. The most common cause of PHPT is a single parathyroid adenoma which 
is detected in about 85% of the cases. Less commonly (~10-15%), PHPT is due to 
multiglandular disease. Fortunately, PHPT is rarely (< 1%) due to an underlying 
parathyroid carcinoma [20]. PHPT is the third most common endocrine disorder 
following diabetes and thyroid diseases [21]. Based on published data, there is a wide 
variation in the prevalence of PHPT. This variation can reflects the population studied 
as well as S-Ca2+ cut offs used for disease recognition. While the most recent Swedish 
study estimated a prevalence of 3.4% in postmenopausal women [22], other studies 
estimated a prevalence of 0.3% in the general population [23, 24]. The exact etiology of 
PHPT is still unknown; however a number of risk factors are identified such as female 
gender, age, family history and history of radiation exposure. The prevalence increases 
with age and postmenopausal women are specifically more prone to develop PHPT [22, 
25]. 
 
Clinical features and diagnosis of PHPT 
 
The clinical presentation of PHPT has changed significantly over the last 20-25 years. 
This is attributed to the introduction of automated calcium measurement which has 
contributed dramatically to the easy and early detection of the disease. Symptomatic 
patients usually represent a minority (~ 20%) of PHPT patients. They usually present 
with clinical features secondary to abnormally high S-Ca2+ such as weakness, lethargy 
and signs and symptoms of renal diseases, most commonly renal stones [26, 27].  
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The skeleton is an important target for PTH and skeletal complications such as bone 
pain and pathological fractures due to loss of bone mass can also be present [28, 29]. 
Other skeletal complications such as osteitis fibrosa cystica are very rarely detected 
nowadays as most patients are diagnosed early in the course of the disease. 
Psychological manifestations such as depression and dementia are also common in 
PHPT patients [30]. Disturbances in the cardiovascular system such as hypertension 
and arrhythmias have been described more commonly in severe forms of PHPT [31, 
32]. However, the majority of PHPT patients are asymptomatic and diagnosed 
incidentally based on high S-Ca2+ [33, 34]. 
 
The diagnosis of PHPT starts with the clinical suspicion in any patients with elevated 
S-Ca2+ (Normal ionized S-Ca2+ range 1.15-1.33 mmol/L). The combination of high  
S-Ca2+ and high or upper normal limit serum PTH (normal PTH range 10-65 ng/L) 
should always indicate hyperparathyroidism until proved otherwise [35]. Except for 
hyperparathyroidism caused by lithium and thiazide treatment, all other causes of 
hypercalcemia are associated with suppressed PTH. Other laboratory findings include 
reduced or lower limit serum phosphate and increased or upper limit 1,25 dihydroxy 
vitamin D. Concurrent vitamin D deficiency may also be detected and can exacerbate 
the hyperparathyroid status [36, 37]. Imaging studies such as ultrasound and 
Technitium99 sestamibi scanning are used to localize the enlarged gland prior to the 
operation [38]. Other imaging techniques such as CT-scan and MRI are also used, but 
less frequently. 
 
Biochemical investigations such as measurement of serum vitamin D, phosphate and 
creatinine as well as 24-hour urinary calcium should be part of the initial evaluation of 
PHPT patients. In addition, as PTH has significant anabolic effect on the skeleton, 
measurement of bone mass (bone densitometry) using dual energy X-ray 
absorptiometry (DXA) has become an important and integral part in the management of 
hyperparathyroidism patients and is recommended for all PHPT patients. 
 
Surgical treatment 
 
Surgical removal of the pathologically enlarged parathyroid gland/glands 
(parathyroidectomy) is the only curative treatment available so far. The decision for 
parathyroidectomy in symptomatic PHPT patients with no concurrent contraindications 
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for anesthesia is usually straight forward; however, since the majority of PHPT patients 
are asymptomatic, controversy exist regarding parathyroidectomy. A practical clinical 
guideline was established to help in selecting patients for surgical treatment [39]. Based 
on this guideline, patients with the following criteria are recommended for 
parathyroidectomy: (1) elevated S-Ca2+ 1 mg above the upper normal limit; (2) 
markedly reduced cortical bone density (T score < - 2.5); or (3) age < 50 years. Patients 
having any of these criteria should be entitled for surgery. The details of the surgical 
approach depend on the underlying pathology. The half life of PTH is short about  
3-5 minutes and intraoperative PTH measurement within 5-10 minutes following gland 
removal has proven to be of clinical use [40, 41]. Several studies have suggested a 
reduction of 50% of intraoperative PTH from baseline measurements as an indication 
for a successful operation [42, 43]. 
 
About 30% of asymptomatic patients will have disease progression on follow-up [44]. 
Bone mass density is not stable over time and monitored patients may experience more 
bone mass loss over time. Parathyroidectomized patients have increased bone mass 
density due to reduced bone turnover [39]. Evidences from postoperative patients 
indicate increased bone mass and reduced fractures [45, 46], reduced incidence of renal 
stones in those with a history of nephrolithiasis and improved neuromuscular 
symptoms. Furthermore, advances in surgical approaches and techniques combined 
with reduced postoperative complications all support the clinical benefits of parathyroid 
surgery over medical and/or monitoring strategies in asymptomatic patients. 
 
Non-surgical treatment 
 
Parathyroidectomy is not always possible or indicated in patients with PHPT. When 
patients do not meet the criteria for surgical removal or have concurrent co-morbid 
conditions, or refuse surgery due to personal decisions, they are monitored regularly by 
annual measurements of S-Ca2+, serum creatinine and bone density and they may be 
offered some sort of medical treatment [39].  
 
Vitamin D supplementation is required for all the patients with a goal of a serum level 
of 20 ng/dl of 25-hydroxyvitamine D and it has been shown to reduce PTH level 
without significant increase in S-Ca2+ level [47]. Dietary calcium restriction is not 
recommended as this may further elevate the serum PTH level [48]. However, 
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excessive intake of calcium should also be avoided. In general, it is advisable to keep 
the dietary calcium intake within the range of 1000-1500 mg/day. In addition to these 
measures, some patients may be offered medical treatment with one or more of the 
following agents: estrogen, selective estrogen receptor blockers, calcimimetic 
cinacalcet and bisphosphonates. However, none of the currently available medical 
treatments are regarded as an advisable alternative to surgery. Furthermore, all the 
available medical therapies need further extended studies to make a final 
recommendation of any of them. 
 
Long term follow up of non-surgically treated patients have showed that about 20-30% 
of them will eventually have disease progressions either as elevated S-Ca2+ or urinary 
calcium and/or reduced bone mass density [46]. Therefore, these patients will have one 
or more of the criteria required for parathyroidectomy and may need to proceed to 
surgery. This finding re-enforces the need for regular long term follow-up of PHPT 
patients treated conservatively. 
 
Secondary hyperparathyroidism (SHPT) 
 
Chronic and persistent stimulation of the parathyroid glands by concurrent decreased 
level of the active form of vitamin D and of S-Ca2+ along with elevated serum 
phosphate leads to hyperplasia of the parathyroid glands and abnormally elevated PTH 
level, a condition called Secondary hyperparathyroidism (SHPT) [49]. The 
overactivation of the parathyroid glands in SHPT represents a compensatory 
mechanism toward any external factor causing deregulation of calcium homeostasis.  
 
The most common cause of SHPT is CKDs where three well recognized biochemical 
changes drive the hyperactivation of the parathyroid glands in these patients and further 
exacerbated by reduced sensitivity of both CASR and vitamin D receptor (VDR) to 
PTH. These changes are represented by declining level of 1,24 dihydroxy vitamin D 
which acts as the earliest stimulus for PTH secretion, followed by hyperphosphatemia 
and hypocalcemia. The sequences of the main biochemical changes are believed to 
correspond to the drop in the glomerular filtration rate (GFR) and therefore decline in 
renal function [49-51]. 
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Patients with SHPT usually suffer from higher morbidity and mortality as compared to 
PHPT patients and this is attributed to the underlying pathology which in most cases is 
a long standing CKD. Therefore signs and symptoms of SHPT patients are those of the 
CKD. These patients usually have higher levels of serum PTH, increased resistance to 
PTH and more severe biochemical disturbances accompanied by severe skeletal and 
sometimes cardiovascular complications. It is very frequent to find some degree of 
SHPT in patients undergoing renal replacement therapy with uncontrolled 
hyperphosphatemia and/or vitamin D replacement [52]. A high incidence of SHPT 
ranging from 30 to 57% among patients with low vitamin D has been reported [53, 54].  
 
Treatment of SHPT is primarily aimed at preventing the deterioration of the condition 
by correcting the biochemical changes and treating the underlying pathology such as 
CKD. Replacement of vitamin D, correction of calcium and phosphate imbalances by 
controlling dietary intake and dialysis as well as treatment with calcimimetics are 
important cornerstones in the prevention of irreversible, tertiary hyperparathyroidism. 
Today, surgical removal of parathyroid glands is reserved for severe cases of SHPT 
patients in which medical interventions fail or when hyperparathyroidism persist after 
renal transplantation. 
 
Tertiary hyperparathyroidism (THPT) 
 
Patients with long standing SHPT can go through a state of progressive hyperactive 
parathyroid gland associated with elevated serum PTH and S-Ca2+, even when the 
underlying pathology was treated. This progressive state of hyperactivity is called 
tertiary hyperparathyroidism (THPT) [52]. This is a very infrequent condition and the 
frequency is even further reduced with improved therapeutic approaches of SHPT. 
 
Familial hyperparathyroidism 
 
Although in the majority of PHPT patients the disease is sporadic, in about 5%, PHPT 
is part of familial syndromes such as multiple endocrine neoplasia type 1 (MEN1) and 
type 2A (MEN2A), hyperparathyroidism-jaw tumor (HPT-JT) syndrome, familial 
isolated hyperparathyroidism (FIHP), familial hypocalciuric hypercalcemia (FHH) and 
severe neonatal hyperparathyroidism (SNHPT). In the following section, these familial 
conditions will be discussed individually. 
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Multiple endocrine neoplasia type 1 (MEN1) 
 
MEN1 is a heritable autosomal dominant syndrome characterized by tumors involving 
the parathyroid glands, the pituitary and endocrine pancreas (MEN1; OMIM # 131100) 
[55]. It is a rare syndrome with a prevalence of 2-3/100,000. However, it is the most 
common cause of familial PHPT and constitutes about 2% of all the causes [56]. The 
penetrance for parathyroid adenoma is very high in this group of patients and may 
reach up to 90% by the age of 50 years. The syndrome has a similar sex distribution 
and usually occurs between the second and the fourth decades of life. In contrast to 
sporadic adenomas, parathyroid disease in patients with MEN1 syndrome is usually 
multiglandular (multiple adenomas or four-gland hyperplasia). These patients are also 
treated surgically; however tumors are more likely to recur following removal [57, 58].  
 
The etiology behind this syndrome is a constitutional mutation of the tumor suppressor 
gene (TSG) MEN1 on chromosome 11q13 (discussed later) [59]. While germline 
mutations inactivate one allele of MEN1 gene, the other allele is usually inactivated by 
the second sporadic hit. Mutations in MEN1 gene can be identified in 70-95% of 
MEN1 patients [60]. In a small percentage of MEN1 patients no mutations can be 
detected in MEN1 gene and this could be due to mutations in the non-coding regions or 
mutations in other related genes which inactivate the menin protein (encoded by MEN1 
gene) as a result. 
 
Multiple endocrine neoplasia type 2A (MEN2A) 
 
PHPT develops in about 20-30% of patient with type 2A of the autosomal dominant 
multiple endocrine syndrome (MEN2A; OMIM #171400). Patients with this syndrome 
carry germline mutations of the RET proto-oncogene [61] and develop tumors in 
multiple endocrine glands such as medullary thyroid carcinoma (MTC), 
pheochromocytoma, and parathyroid adenomas [62]. Hyperparathyroidism in MEN2A 
is usually mild, clinically resembles sporadic cases of PHPT and is almost always 
caused by underlying benign parathyroid tumors [63]. 
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Hyperparathyroidism-jaw tumor (HPT-JT) syndrome 
 
HPT-JT is an autosomal dominant syndrome characterized by tumors of parathyroid 
glands, jaw bones, uterus as well as various kidney lesions (HPT-JT; OMIM 607393). 
Most of PHT-JT patients are presenting with features of PHPT and in about 10-15% of 
the cases, it is due to a parathyroid carcinoma [64-66]. This syndrome is caused by 
constitutional mutation of CDC73/HRPT2 gene (discussed later) [66] which is 
identified in about 50-75% of the patients. Numerous mutations, most of which are 
expected to cause inactivation of the gene, have been identified scattered through the 
CDC73 gene, but no hotspot has been reported thus far [67]. In contrast to MEN1, 
somatic mutations in CDC73 are uncommon in parathyroid adenomas while they are 
frequently detected in parathyroid carcinomas [66-69]. 
 
Familial hypocalciuric hypercalcemia (FHH) 
 
FHH is an autosomal dominant condition (FHH; OMIM #145980) characterized by 
slightly elevated or upper normal serum PTH, elevated S-Ca2+ and reduced excretion of 
urinary calcium. Patients with FHH carry a heterozygous germline mutation in the 
CASR gene rendering the receptor much less sensitive to changes in the extracellular 
calcium [70, 71]. Two other loci on chromosome 19p and 19q have been reported to be 
linked to other families with FHH [72, 73]. 
 
Severe neonatal hyperparathyroidism (SNHPT) 
 
This is a very rare variant of FHH due to homozygous mutations in CASR and results in 
a fatal condition in the newborn [74]. 
 
Familial isolated hyperparathyroidism (FIHP)  
 
FIHP is a clinical entity identified when there is hyperparathyroidism without any 
specific features of MEN1, HPT-JT or FHH syndromes (OMIM #146200) [75]. In a 
subset of families the patients exhibit mutations of MEN1, CDC73 or CASR [76]. 
However, in most families no causative mutations have been identified. One study has 
suggested an additional locus on chromosome 2 as potentially involved in the 
pathology of FIHP [77]. 
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DISEASES OF THE PARATHYROID GLANDS – HYPOPARATHYROIDISM 
 
In contrast to hyperparathyroidism, the condition hypoparathyroidism refers to reduced 
glandular activity with abnormally reduced PTH secretion leading to hypocalcemia. 
Hypoparathyroidism is most commonly encountered after neck surgery due to 
inadvertent damage to the parathyroid glands or removal of all parathyroid glands with 
failure of re-implantation. In the majority of the cases, hypoparathyroidism is sporadic, 
however, it also occurs as a part of complex autoimmune diseases or as an isolated 
entity such as the autosomal dominant familial isolated hypoparathyroidism [78, 79]. 
The clinical signs and symptoms of hypoparathyroidism are predominantly related to 
hypocalcemia such as muscle spasms, numbness and paresthesias. In severe cases, the 
patient may experience life threatening complications such as seizures, tetany and 
laryngeal spasm [80]. The diagnosis is mainly based on the detection of concurrently 
low PTH and low S-Ca2+. The standard treatment of hypoparathyroidism is correction 
of hypocalcemia and the accompanying reduced vitamin D by the supplementation of 
oral calcium and vitamin D [81]. 
 
TUMORS OF THE PARATHYROID GLANDS 
 
Tumors of the parathyroid glands can be benign or malignant and are broadly classified 
as adenomas, carcinomas and atypical adenomas. 
 
Parathyroid adenoma  
 
Parathyroid adenoma is the most common type of parathyroid tumors and responsible 
for about 85% of PHPT cases [20]. In sporadic cases, one single parathyroid gland is 
usually enlarged and has hyperactive state causing excessive secretion of PTH. Double 
adenomas are also reported, but they are rare [82].Parathyroid adenomas are more 
frequently detected in postmenopausal women [20]. The median glandular weight 
reported is 650 mg [83]; however, parathyroid adenomas as large as 110 grams have 
been reported [84]. Typical parathyroid adenomas appear as reddish brown in color 
with soft consistency encapsulated in a thin fibrous layer (Figure 6). In about 50-60% 
of the cases there is also a yellowish brown rim of glandular tissue most often found 
close to the vascular hilus of the gland and it represents the remnant of the normal 
parathyroid gland commonly referred to as “normal rim” [20]. 
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The majority of parathyroid adenomas are composed of chief cells, with a smaller 
proportion consisting mainly of oxyphil cells [85]. Microscopically, the cells usually 
have mild degree of nuclear polymorphism with reduced intracytoplasmic fat contents 
as well as an overall reduction in the number of adipocytes. Identification of an intact 
thin fibrous capsule surrounding the parenchyma cells and the presence of a “normal 
rim” can be of great diagnostic value in differentiating adenomas from malignant 
parathyroid tumors and hyperplasia, respectively (Figure 3B) [20]. 
 
                       
 
     Figure 6. Macroscopic appearance of a parathyroid adenoma. 
 
Parathyroid carcinoma 
 
Carcinoma of the parathyroid gland is a rare malignancy and it accounts for less than 
1% of PHPT causes [86, 87]. Parathyroid carcinoma has no gender preferences and it is 
usually diagnosed at younger ages as compared to adenomas. However, it can occur at 
any age. The clinical presentation of patients with parathyroid carcinoma is usually 
very aggressive and characterized by a palpable neck mass, hoarseness of voice, very 
high S-Ca2+ (3.5 mmol/L) and serum PTH (usually 4 fold normal). Patients may also 
have skeletal, kidney and other body organs complications. However, none of the 
clinical features are exclusive and parathyroid adenomas could have any of these 
features. Certain pathological features such as large tumor size, marked nuclear atypia, 
trabecular growth pattern and thick fibrous bands are more frequently seen in 
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parathyroid carcinomas (Figure 3C), but again these features can be also seen in 
atypical adenomas (discussed below) which further complicate the diagnosis.  
However, only capsular penetration and invasion of the surrounding tissue, local 
recurrence and distant metastasis can set the final diagnosis. Unfortunately, these 
diagnostic criteria can only be detected in advanced stages of the disease [88]. The 
difficulty in correct diagnosis and therefore difficulty in selecting best treatment 
modality and follow-up protocol urged the need for molecular markers which can 
identify carcinomas in pre or intraoperative time. Studies have identified a number of 
potential markers each with different sensitivity and specificity for the detection of 
carcinoma cases. Loss of parafibromin expression, the protein product of HRPT2 gene, 
is a well studied marker which is integrated into the diagnostic work up whenever 
parathyroid carcinoma is suspected [89-91]. Along with parafibromin, the proliferation 
marker Ki67 is also used as additional diagnostic aid as parathyroid carcinomas usually 
have a higher proliferation index than adenomas [92]. 
 
Atypical parathyroid adenoma 
 
Atypical adenomas refer to a group of parathyroid tumors with histopathological 
features that overlap with parathyroid carcinomas [93, 94]. The differentiation between 
parathyroid carcinoma and atypical parathyroid adenoma is a diagnostic challenge and 
yet very important since parathyroid carcinoma requires a more extensive surgery and a 
closer follow-up [93]. The diagnosis of atypical adenoma is based on the identification 
of any two of the following histological features: incomplete capsular invasion, fibrous 
bands, pronounced trabecular growth pattern, mitotic activity more than one mitosis per 
10 high-power fields and tumor necrosis (Figure 3D) [94].  
 
Atypical parathyroid adenomas were previously referred to as equivocal carcinomas 
and several studies raised the question whether these atypical cases carry any malignant 
potential [20]. These uncertainties necessitate close follow-up of patients diagnosed 
with atypical adenomas in order to avoid any possible misdiagnosed parathyroid 
carcinoma [61]. 
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MOLECULAR GENETIC BACKGROUND OF PARATHYROID TUMORS 
 
Clonal development is a prominent feature of cancer as it provides selective growth 
advantage to the tumor cell. The debate on whether parathyroid tumors are monoclonal 
or polyclonal in growth lasted for a long time until a number of studies showed 
experimentally the monoclonal nature of parathyroid tumors using chromosome X 
inactivation [95, 96].  
Many studies investigated the molecular genetic mechanisms involved in parathyroid 
tumors development and they had considerable contribution to the current insight into 
this disease (Table 1). Studies of familial cases of PHPT provided valuable information 
on the genetic of sporadic cases of parathyroid tumors and have led to the identification 
of two important TSGs which are: 
 
Multiple endocrine neoplasia type 1 (MEN1) gene 
 
The tumor suppressor MEN1 is a located in chromosomal region 11q13. MEN1 has 10 
exons and it is about 9.8 kb in size and encodes for a 610 amino-acid nuclear protein 
called menin (Figure 7). The MEN1 gene was first mapped to 11q13 in family studies 
[59]. This gene was subsequently identified as the underlying etiology in MEN1 
patients and MEN1 mutations were detected in the majority of the cases [97, 98]. This 
has motivated the search for MEN1 mutations in sporadic cases of PHPT which 
identified mutations in about 25% of the cases [99, 100]. A more recent study using 
whole exome sequencing has identified MEN1 mutation in 6/16 (35%) of sporadic 
parathyroid adenomas [101]. Mutational analyses have revealed more than 400 
different MEN1 mutations in parathyroid tumors, most commonly of the type that 
inactivates the protein such as truncating deletions or insertions and/or nonsense type 
which inactivate the gene [102]. Constitutional MEN1 mutations have been also 
reported in clinically apparent sporadic cases of parathyroid adenomas [103, 104]. 
Furthermore, loss of heterozygosity (LOH) at the MEN1 gene locus is frequently 
detected in parathyroid adenomas in about 30% of cases, half of which have MEN1 
mutations [100, 105]. In contrast to adenomas, MEN1 mutations are rare in parathyroid 
carcinomas and it has only been reported in four cases so far [106-109]. 
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The nuclear protein menin is involved in key cellular functions such as growth, 
proliferation and cell cycle control as well as DNA repair [111]. Menin acts as a 
transcription repressor through the interaction with Jun D, a member of the 
transcription factor family AP-1/fos Jun and also through recruitment of histone 
deacetylase complex [112-115]. Menin has histone methyltransferase activity which is 
involved in controlling cell growth through upregulation of the cyclic dependant kinase 
inhibitors p16 and p18 [116]. In addition, menin promotes gene transcription via the 
interaction with an important member of the TGF-beta family, Smad3. While in 
parathyroid glands, TGF-b inhibits cellular proliferation and PTH production, 
inactivation of menin will remove this inhibition and will therefore enhances cellular 
proliferation and increases PTH secretion [117, 118]. 
 
 
 
Figure 7. Diagrammatic representation of MEN1 gene and its product, menin with 
proposed functions. 
 
Hyperparathyroidism 2 (HRPT2)/CDC73 gene 
 
The CDC73 gene is a known TSG located on chromosome 1q32 and has 17 coding 
exons. Similar to MEN1, mutations of the CDC73 gene were first detected in familial 
forms of PHPT, namely the HPT-JT syndrome where the majority of patients were 
found to harbor an inactivating CDC73 mutation [66]. As parathyroid tumors within 
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HPT-JT syndrome carry a high risk of malignancy, CDC73 mutations were also 
expected to have a role in parathyroid carcinomas. This speculation was then supported 
by studies showing CDC73 mutations in the majority of sporadic parathyroid 
carcinomas [119]. The reported frequencies of somatic CDC73 mutations detected in 
sporadic parathyroid carcinomas vary between 67% up to 100% [68, 69, 119]. In 
contrast to carcinomas, CDC73 mutation is rare (~4%) in sporadic parathyroid 
adenoma [68, 120, 121]. Constitutional mutations of CDC73 have been also detected in 
clinically apparent sporadic cases of parathyroid carcinomas [122, 123].  
 
 
Figure 8. Diagrammatic representation of HRPT2/CDC73 gene and its product, 
parafibromin with proposed functions. Modified from reference [91]. 
 
The CDC73 gene encodes a 531 amino-acid tumor suppressor protein called 
parafibromin. Parafibromin has multiple important cellular functions (Figure 8). It is 
part of the of RNA polymerase II-regulatory Paf1 complex which is involved in gene 
transcription mediated by histone methylation in the promoter and coding regions of 
specific genes [124]. It also regulates the cell cycle via the regulation of cyclin D1 
expression [125]. Parafibromin is a ubiquitously expressed protein and it is mainly 
located in the nucleus where it acts as a transcription factor and regulates transcription 
of certain genes such as cMYC [126]. It can be also found in the cytoplasm where it is 
involved in the organization of the cytoskeleton through binding to actin binding 
proteins actinin-2 and actinin-3 [127]. Studies have shown that over-expression of 
parafibromin by transfected cells can induce apoptosis [128] while parafibromin null 
mice do not survive and die in utero [129]. 
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Other genetic alterations reported in parathyroid tumors 
 
One of the earliest genetic abnormalities identified in parathyroid adenomas is the 
chromosomal rearrangement of cyclin D1/PRAD1 (parathyroid adenomatosis 1) proto-
oncogene [130-132]. This rearrangement is a pericentromeric inversion on 
chromosome 11 that positions the 5' PTH regulatory region, originally located on 11p, 
to the upstream of the cyclin D1 gene located on 11q, leading to over-expression of 
cyclin D1 (Figure 9). Although this genetic alteration has been reported infrequently, 
overexpression of cyclin D1 is more commonly observed in about 20-40% of sporadic 
parathyroid adenomas and even more frequently in parathyroid carcinomas [133-135]. 
Cyclin D1 is a proto-oncogene that plays a major role in regulation of the cell cycle and 
over-expression of this gene leads to proliferation and cell growth [136]. However, no 
cyclin D1 mutations have been reported in parathyroid tumors [137]. 
 
Mutations of RET (REarranged during Transfection) oncogene is detected in patients 
with MEN2A. Although no RET mutations have been reported in sporadic parathyroid 
tumors, over-expression of this gene has been demonstrated in sporadic cases [138]. 
 
Reduced expression of CASR has been repeatedly reported in parathyroid tumors. 
However, only very few studies have reported mutations in this gene [75, 139-141]. In 
a recent retrospective study, reduced CASR expression was associated with 
significantly poorer prognosis in parathyroid carcinoma patients [142]. 
 
A number of potential candidate genes known to be commonly mutated in other tumor 
types such as RAS, RB, TP53 have also been investigated in parathyroid tumors and 
apart from only one study which reported TP53 mutation in a single anaplastic 
parathyroid carcinoma, no other mutations have been reported [131, 143-147]. 
 
 In addition to mutations, other genetic aberrations such as recurrent DNA copy number 
alterations (CNAs) and LOH have been also reported in parathyroid tumors. Examples 
of the most commonly detected recurrent CNAs and LOH are losses in 1p, 3q, 6q, 9p, 
11p, 11q, 13 and 15q and gains of 16p and 19p [148-154]. Furthermore, two different 
chromosomal translocations have been reported in parathyroid adenomas including a 
t(1;5)(p22;q32) [155] and a t(4;13)(q21;q14) [156]. However, the functional 
consequences of these translocations have not been identified yet. 
 29 
 
 
Figure 9. Illustration of cyclin D1/PRAD1 chromosomal rearrangement. Modified from 
reference [137]. 
 
EPIGENETICS 
 
Epigenetics is the study of heritable and potentially reversible changes in cellular 
information which are not due to alterations in DNA sequence [157]. The field of 
epigenetics has undergone a rapid and considerable development over the last 20 years 
and its role is clearly demonstrated in both normal and pathological conditions 
including human cancers [158]. Epigenetic mechanisms regulate gene function 
independent of the DNA sequence and can be regarded as the interface between 
genotype and phenotype. Consequently, epigenetics can explain the functional and 
morphologic differences between different cell types in any organism, although these 
cells all have identical genetic material. 
 
Epigenetic mechanisms are involved in many important cellular processes such as 
embryonic development, cellular growth and differentiation, X chromosome 
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inactivation and genomic imprinting as well as protection against viral genome 
integration [159, 160]. Different epigenetic mechanisms exist, all of which are essential 
for regulation of gene function. These mechanisms include: DNA methylation, histone 
modifications and chromatid remodeling, and RNA-mediated gene silencing. 
 
DNA methylation 
 
DNA methylation is the most studied and the best characterized epigenetic mechanism. 
It involves covalent binding of a methyl group to the C-5 position of cytosine base of a 
cytosine-guanine (CpG) dinucleotide (Figure 10) [158]. 
 
 
 
Figure 10. DNA 5-methylcytosine methylation. Modified from reference [161]. 
 
DNA methylation usually occurs at clusters of CpG dinucleotides known as CpG 
islands (CGIs) [158]. They are defined as clusters of CpG dinucleotides stretching for 
about 200 to 500 bp with GC contents of over 50% and observed/expected GC contents 
of 60%. CGIs are localized at the promoters of more than half of the human genes and 
they are usually unmethylated under normal conditions [162, 163]. The co-localization 
of the CGIs with gene promoters provide a more chromatin permissive state [164] and 
can act as a distinguishing mark for transcriptional start sites [165]. While CGI 
promoter hypermethylation leads to transcriptional repression and gene silencing [166], 
hypomethylation of CGIs is associated with reactivation of repressed genes [167]. 
However, the later mechanism is less well characterized. Many TSGs involved in 
different cellular processes such as DNA repair, cell cycle, apoptosis and angiogenesis 
are frequently silenced by aberrant DNA promoter methylation in various human 
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cancers and at different stages of tumor development [168]. There are many examples 
of TSGs that are inactivated by promoter methylation, for e.g. RB, VHL, hMHL1, 
BRCA1 and p16INK4 a [169-172]. Aberrant CGI methylation is recognized as a hallmark 
of cancer [159]. In addition to gene-specific DNA methylation changes, alterations in 
DNA methylation can also occur at genomic regions other than gene promoters and 
cause alterations in global methylation status [164]. Global hypomethylation occurs 
mainly at repetitive sequences such as long interspersed nuclear elements-1 family 
member L1 (LINE-1), inducing chromosomal instability, translocations, gene 
disruption and reactivation of endoparasitic sequences [164]. Hypomethylation of 
LINE-1 has been reported in many human cancers such as cancers of breast, lung, 
bladder and liver [165]. More recent genome-wide methylation analyses in colon 
cancer have revealed frequent hypermethylation of CpGs at genomic regions of less 
dense GC contents located at about 0.5-2 kb upstream to the promoter and have been 
termed “CpG shores” [173]. This study found that most tissue-specific DNA 
methylation occurs at CGI shores, rather than on the islands themselves. 
 
DNA methylation induced gene transcriptional repression occurs through a number of 
proposed mechanisms. Two different, but biologically relevant DNA methylation 
mechanisms are described (Figure 11). First methylation of CGIs at gene promoters can 
act as a physical hindrance and block the access of transcription factors to the 
transcription starting site and prevent the initiation of transcription [174]. A second 
proposed mechanism suggests that DNA methylation will recruit histone modifying 
and chromatin-remodeling complexes to methylated sites which act as repressor 
proteins and therefore trigger gene silencing [175, 176]. Among these repressor 
proteins are four members of the methyl binding proteins (MBD1, MBD2, MBD3 and 
MeCP2), which act as methylation-dependant transcription repressors [161].  
 
Methylation of CpGs is mediated by members of the DNA methyltransferase (DNMTs) 
family of enzymes which catalyze the transfer of a methyl group from S-adenosyl 
methionine to DNA. DNMTs are mainly classified into de novo and maintenance 
DNMTs [177]. De novo DNMTs include DNMT3A and DNMT3B which are highly 
expressed in embryonic stem cells and downregulated in differentiated cells and are 
responsible for establishing the pattern of methylation during embryonic development 
[175]. DNMT1 acts as a maintenance DNMT and is responsible for maintaining the 
methylated state during cell division [178]. 
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Figure 11. Mechanisms of gene silencing by DNA methylation. (A) Transcriptionally 
active, unmethylated gene promoter. (B) Silenced gene due to promoter 
hypermethylation. (C) Silenced gene due to methylation-recruited transcription 
repressors. Modified from reference [179]. 
 
Histone modifications and chromatid remodeling 
 
This describes posttranscriptional modifications of N-terminal of histone tail protruding 
from the nucleosomes. Various histone modifications are identified and include 
acetylation, methylation, phosphorylation, ubiquitination, SUMOylation and ADP 
ribosylation which will modify the chromatin state to be active or repressive (according 
to the type of the modification) [180]. Studies have shown that histone modifications 
are correlated and occur in connection to each other, a process that has later been 
termed as the “histone code” [181]. Although histone modifications are not as well 
studied as DNA methylation, the interest to investigate this modification is growing. 
Different patterns of histone modifications have been identified in a variety of human 
tumors and are found to be correlated with tumor stage and prognosis [182, 183]. 
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RNA-mediated gene silencing 
 
Posttranscriptional silencing by small non-coding RNAs has become increasingly 
recognized as an epigenetic mechanism of gene function control. Example of non 
coding small RNAs are microRNA (miRNA) (Figure 12) which are about 20-22 
nucleotides long usually located in the introns or exons of the protein coding genes in 
70% of the cases [184]. They can also be found in the intergenic regions in about 30% 
of the cases [158, 160]. miRNA can directly interact with mRNA causing either its 
degradation or repression [185] and they have important functions such as regulation of 
cellular proliferation, differentiation, apoptosis, and development [186]. The number of 
known miRNAs has dramatically increased in the last 5-10 years. Interestingly, 
miRNAs can function as tumor suppressors or as oncogenes and many studies have 
shown that deregulation of miRNAs are involved in different pathological conditions 
including cancer [187]. This class of small non-coding RNAs is now being explored to 
have great cancer diagnostic and prognostic potentials as emerging evidence revealed 
that the pattern of miRNAs expression correlate well with clinicopathological 
characteristics and outcome of different cancer types [188]. 
 
 
 
Figure 12. MicroRNA and posttranscriptional regulation of gene expression via RISC 
(RNA-induced silencing complex). Modified from reference [189]. 
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Epigenetic background of parathyroid tumors 
 
Studies of epigenetic mechanisms have also been conducted in parathyroid tumors, 
however with a much lesser frequency than genetic studies. Among the earliest 
published report is a study which investigated tissue and gene-specific expression of 
PTH by parathyroid glands using a restriction enzyme-based method [190]. They 
reported hypomethylation of DNA sequences in proximity to the PTH gene while the 
same sequences were hypermethylated in control non-PTH expressing tissues. 
Although this study analyzed only normal parathyroid tissues and did not find any 
correlation with PTH secretion in the parathyroid glands themselves, it suggested a role 
of DNA methylation in association with PTH gene and tissue-specific expression. Few 
studies have specifically analyzed methylation of CDC73/HRPT2 and all [191, 192], 
but one [193], excluded hypermethylation as a silencing mechanism. Taken together, 
the overall data do not support regulation of HRPT2 by methylation. This will be 
further discussed in this thesis (study III and IV). We have analyzed parathyroid tumors 
for promoter methylation of several genes and we found frequent hypermethylation of 
APC and RASSF1A [194]. On a genome-wide scale, a recently published study 
identified a number of hypermethylated genes with possible involvement in parathyroid 
tumorigenesis [195]. Among the significantly hypermethylated genes were CDKN2B, 
CDKN2A, WT1, SFRP1, SFRP2, and SFRP4.  
 
In addition to DNA methylation, genome-wide miRNA profiling of parathyroid tumors 
has revealed interesting patterns with potential capability of distinguishing carcinomas 
from benign parathyroid tumors [196, 197]. For example, one study found the 
expression of miR-296 and miR-222 was significantly different between carcinomas 
and adenomas. More interestingly, a recent study has identified a miRNA cluster called 
C19MC located on 19q13.4 which was significantly associated with parathyroid 
carcinoma and positively correlated with S-Ca2+, PTH and tumor weight [198]. 
Furthermore, this study also found C19MC promoter hypomethylation in 50% of the 
tumors which significantly associated with S-Ca2+ and metastatic disease, further 
supporting the role of epigenetic mechanisms in parathyroid tumor development. More 
studies are required to validate and identify potential genes that are regulated by 
methylation as well as to define the methylation profile of different parathyroid tumor 
types and subtypes. 
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AIMS OF THE STUDIES 
 
The general aim of this thesis was to contribute for better understanding of the genetic 
as well as epigenetic alterations involved in parathyroid tumors development. More 
specifically, the studies have aimed at the following: 
 
• Defining the genetic profile of large parathyroid adenomas (LPTAs) and 
determining whether LPTAs display malignant potential (study I). 
 
• Identifying recurrent minimal regions of DNA copy number alterations which 
may harbor potential tumor suppressor genes and oncogenes (study I). 
 
• Investigating a possible association between constitutional APC mutations and 
parathyroid tumors (study II). 
 
• Characterizing the genetic alterations in parathyroid tumors with established 
CDC73 mutations (study III). 
 
• Understanding mechanisms of CDC73 gene inactivation in parathyroid tumors 
(study III). 
 
• Studying the role of DNA promoter methylation in the regulation of genes 
potentially involved in parathyroid tumorigenesis and determining whether the 
mutational status of MEN1 or CDC73 gene can alter gene-specific as well as 
global methylation profile in parathyroid tumors (study IV). 
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METHODS 
 
Mutational analysis by Sanger sequencing 
 
DNA sequencing is the golden standard approach for mutation screening. In our studies 
(study I, II and III) we have used the dye-terminator Sanger sequencing method for 
mutational screening of APC, MEN1 and CDC73. The principle of this method relies 
on the use of fluorescently labeled chain terminator dideoxynucleotides (ddNTP’s) 
(Figure 13) [199]. This ddNTP differs from normal deoxynucleotides as it has a 
hydrogen group at the 3´carbon instead of a hydroxyl group. The advantage of this 
modification is that when ddNTP is incorporated into the synthesized DNA sequence it 
immediately terminates the reaction and blocks further addition of any ddNTPs. The 
protocol starts with amplification of the target sequence with specific primers using 
PCR. The PCR product is then purified to remove any unincorporated dNTPs using 
either chemical or enzymatic cleanup processing.  
 
 
Figure 13. Principle of chain terminator DNA sequencing.  
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The sequencing reaction mixture contains: DNA polymerase, the four ddNTPs (G, A, T 
and C) labeled in one fluorescent dye color each, the single stranded template of the 
specifically amplified PCR product, a specific sequencing primers, unmodified dNTPs, 
and other buffers required for the sequencing reaction. The sequencing reaction is run 
in the sequencing machine and it is a semi-automated process. When incorporated by 
DNA polymerase each labeled ddNTP will emit light at different wavelengths that will 
be captured and reported as a colored peak in the chromatogram. The reaction 
continues until the specified region has been fully sequenced. The resulted 
chromatogram will be cross-referenced with a reference genome and any mismatch in 
the target sequence will be further analyzed for possible mutations. 
 
Array comparative genomic hybridization (a-CGH) 
 
Tumors are characterized by DNA copy number alterations (CNAs) that are the 
consequences of structural chromosomal alterations of various types and complexity 
such as amplifications, deletions, translocations or gain and loss of a chromosome 
[200]. Knowledge of CNAs can have immediate clinical use in diagnosis and in 
some cases provide useful prognostic information such as in assessing the prognosis 
in breast [201] and prostate cancers [202]. Furthermore, it can aid in therapeutic 
judgments such as in chronic lymphocytic leukemia treatment [203].  
 
Different techniques exist for the study of CNAs, each with its own advantages and 
disadvantages. Examples of such techniques are fluorescence in-situ hybridization 
(FISH), karyotyping and CGH. In the recent years tremendous improvement in the 
resolution and throughput has occurred. While next generation sequencing currently 
provide the most comprehensive information of the whole genome, some of these 
techniques are still successfully used in both research and clinical practice such as 
FISH and microarray. 
 
Array CGH (a-CGH) is a powerful and a precise tool developed to detect and 
quantify genomic aberrations and map them directly onto the sequences of the 
human genome. It is a tool for cancer gene discovery and understanding disease 
pathogenesis. The main advantage of a-CGH is that the entire genome can be 
scanned for CNAs in a single experiment [204, 205]. The primary goal is to identify 
regions of recurrent CNAs of losses and gains where TSGs and oncogenes can 
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reside, respectively. Different a-CGH platforms exist. The main differences lie in the 
type, size and spacing of the genomic sequence printed on the microarray slides. 
These features will determine the final resolution of the applied microarray platform. 
An early platform which we also used in our studies is BAC arrays. This type of 
microarray platform implement large inserts of DNA produced from bacterial 
artificial chromosome (BAC) inserts. The resolution varies based on the type of the 
BAC arrays and it has developed from 24K to 38K which is the latest for BAC tiling 
arrays. We have used human BAC 38K arrays (study I & III) generated at the 
SCIBLU Genomics Centre at Lund University, Sweden (www.lu.se/sciblu). These 
arrays contain about 38,000 BAC clones (CHORI BACPAC resources) 
(http://bacpac.chori.org/ genomicRearray.php) arranged in a tiling fashion resulting 
in a final resolution of about 100-150 kb. This platform can provide sufficient signal 
intensity to quantitatively detect single copy number changes as well as homozygous 
deletions and high-level amplifications. However, one main disadvantage of a-CGH 
in general, is the inability to detect balanced translocations and other copy number 
neutral alterations. 
 
Array CGH method basically relies on hybridization where DNA will only bind to 
complementary genomic sequences spotted on the array slides (Figure 14). Tumor 
and normal DNA are fluorescently labeled in different colors. Both tumor and 
normal DNA will compete for binding to the genomic sequences on the slide. When 
there are no CNAs in the tumor, i.e. diploid, theoretically the combined color will 
give a yellow fluorescent signal. When the tumor has a deletion or a gain, the 
fluorescent color will be either red or green based on the initial labeling. In a-CGH, 
genomic DNA is labeled in vitro by random priming to incorporate fluorescently 
labeled nucleotides, usually Cy3 (green) or Cy5 (red). The hybridized microarray 
slide will be scanned and the features will be extracted using special feature 
extractions software. The extracted raw data will be further analyzed after several 
steps of normalization and smoothing to remove unwanted background and avoiding 
false positive effects. The signal intensity log2 ratio will be calculated for each 
single feature on the array slide and the expected log2 ratio of a single copy gain in a 
diploid genome, when hybridized versus normal genomic DNA, would be + 0.58, 
and -1 for a single copy loss. In practice, log2 ratios can range from – 4 for 
homozygous deletions to log2 ratio > 6 for high-level amplifications [206]. 
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 Figure 14. Principle of a-CGH 
 
Single nucleotide polymorphism microarray (SNP array) for loss of 
heterozygocity (LOH) analysis 
 
LOH is a common type of alteration and refers to a change from heterozygous to 
homozygous state in a paired tumor genome as compared to constitutional genome. 
LOH is a common mechanism of TSG inactivation and are frequently identified in 
human tumors (Figure 15) [207]. Several methods are available for identifying 
LOH, for example SNP-based analysis, microsatellite DNA analysis and SNP-based 
Pyrosequencing. SNPs are very common human genetic variations and are highly 
conserved during evolution making these polymorphic loci excellent markers for 
studying LOH. SNP-based microarrays provide a high throughput genome-wide 
technique for screening LOH events. This technique can also simultaneously 
provide genome-wide DNA copy number information in a single experiment.  
This method involves hybridization-based microarray analysis, where the chip 
contains highly condensed SNPs and is hybridized to fluorescently labeled samples. 
The resolution of SNP microarrays rely on the density of the SNPs printed on the 
microarray chip.  
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We have used the Affymetrix 250K genotyping chip (Affymetrix Inc., Santa Clara, 
CA, USA) in our study (study III). This platform has about 25,000 SNPs distributed 
randomly throughout the genome. Four rows of 25-mer oligonucleotides are used as 
a detector for each SNP loci in the chip. Two of them perfectly match SNP allele A 
or SNP allele B, while the other two contain single-base mismatch at various 
positions. SNP-based LOH analysis requires that tumor and normal samples being 
allelotyped on separate chips. However, with current SNP databases, comparison to 
non-paired online SNP databases generated from normal individuals is feasible. 
Following hybridization, the chips are scanned and the genotyping calls (LOH, 
retention of heterozygosity, uninformative or no call) are made using a special 
software which will calculate the ratio of allelic imbalance at each individual loci 
investigated. 
 
Figure 15. Principle of loss of heterozygosity (LOH). Redrawn from reference 
[208].  
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Bisulfite Pyrosequencing 
 
Different techniques are available for DNA methylation analysis. However, the 
majority of these methods lack enough sensitivity and have time consuming labor-
intensive protocols. In addition, some of these methods such as restriction enzyme-
based techniques require large amount of DNA for analysis and the sensitivity is 
limited to those sites recognized by the enzyme. Bisulfite (BS) Pyrosequencing was 
developed to circumvent those issues and has become the standard method for 
quantitative DNA methylation analysis. Pyrosequencing is principally a sequencing 
by synthesis method which provides a powerful analytic tool for accurate 
quantification of multiple successive CpG dinucleotides with high resolution and 
reproducibility. This method uses a simple and easy to follow protocol which 
requires a very small amount of DNA for analysis. It relies on BS modification 
which will convert unmethylated cytosine bases in CpG dinucleotides to uracil (U) 
and then to thymine (T) in the subsequent PCR amplification step, while methylated 
cytosine will remain methylated (Figure 16).  
 
 
 
Figure 16. Bisulfite modification and subsequence processes in Pyrosequencing. 
Redrawn from Pyrosequencing database, Qiagen. 
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BS converted DNA is amplified with specific methylation primers designed to 
specifically amplify the target CpG sites. For Pyrosequencing reaction, a single 
stranded BS modified DNA will be hybridized to specific sequencing primer and 
run in the Pyrosequencing machine. The Pyrosequencing reaction itself consists of a 
cascade of very well synchronized enzymatic reactions including four enzymes, 
DNA polymerase, ATP sulfurylase, luciferase, and apyrase (Figure 17).  
 
Upon the addition of the first complementary nucleotide by DNA polymerase, there 
will be release of a pyrophosphate (ppi) in a quantity equimolar to the amount of the 
incorporated nucleotide. The released ppi will be converted to ATP by the action of 
ATP sulfurylase. The enzyme luciferase catalyzes the conversion of luciferin to 
oxyluciferin which will generate light in an amount proportional to the amount of 
ATP generated. The light is captured by a charge coupled device (CCD) camera and 
presented as a peak in the resulting Pyrogram. The height of the peak is proportional 
to the number of nucleotides incorporated and will be recorded graphically as a 
Pyrogram. The role of the apyrase enzyme is to remove any unincorporated 
nucleotides from the reaction mixture. This process will be continued until the target 
genomic region is sequenced. The resulting raw data generated from the 
Pyosequencing reaction will be analyzed using pyromark software to quantify the 
methylation status. The ratio of the methylated to the unmethylated cytosine at each 
CpG dinculeotide will represent the percentage of methylation for that particular 
CpG site.  
 
For our studies, we have compared the average methylation density of tumor 
samples for each gene to the methylation density of the normal parathyroid samples. 
A difference of more than 10% in the mean methylation density was regarded as 
significant. 
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Figure 17. Principle of Pyrosequencing reaction. 
 
Immunohistochemistry (IHC) 
 
IHC is a well established and a widely used technique for the detection and sub-
cellular localization of proteins using labeled antibodies specifically directed against 
the proteins of interest. The methodology of IHC can vary widely depending on the 
tissue type studied, the targeted protein as well as the required degree of detection 
sensitivity and specificity. However the basic principle of IHC remains the same 
involving a specific antigen-antibody reaction. In general, the protocol starts with 
fixation of the tissue most commonly using formalin fixation to produce formalin-
fixed paraffin embedded tissue block. The paraffin block will be further processed 
and cut into sections of about 5μm thickness and fixed onto the surface of a glass 
slide. In order to uncover the antigenic sites, the slides are treated for what is called 
antigen retrieval were the slides are preheated allowing breakage of the protein 
cross-links created by the fixation step. 
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Two protein detection methods are used in IHC (Figure 18). The direct method uses 
only one labeled primary antibody to detect the target protein. This method has the 
advantages of being quick and short, but has the drawback of reduced sensitivity. In 
contrast, the indirect method uses two sets of antibodies. The first primary antibody 
is not labeled and used to detect the target antigen while the secondary antibody are 
labeled and directed to detect the first primary antibody. The indirect method has 
amplified signal intensity therefore has increased sensitivity; however it is more 
time consuming and has longer protocols. Stained IHC slides are examined under 
light microscope or scanned with special scanner for visualization, detection and 
sub-cellular localization. In study I and II, we used the indirect avidin-biotin 
complex (ABC) method. 
 
 
 
Figure 18. Immunohistochemistry (IHC). Direct and indirect methods of protein 
detection. 
 
TaqMan DNA copy number analysis 
 
This method is used for DNA copy number prediction at a specific genomic locus. 
We have used this method in our studies (study I, II and III) for validation of 
selected loci with recurrent CNAs as well as for CDC73 and APC copy number 
estimations. This is a quantitative PCR-based method implementing Taqman 
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chemistry with a similar approach to standard real time based qPCR. The target and 
reference primers are labeled with FAM and VIC dyes, respectively and both are run 
simultaneously in a duplex real-time PCR. The reference primer is designed to 
detect genomic sequence with known diploid copy number and used as an internal 
control. The reaction is run in triplicates in a qRT-PCR machine using standard 
amplification method and target DNA copy number is predicted using relative 
quantification method (ΔΔ Ct) [209]. In order to estimate ΔΔ Ct, the difference 
between target Ct and reference Ct (ΔCt) is calculated and compared to a calibrator 
known to have two copies of the target loci. The copy number of the target is 
calculated to be two times the relative quantity. Raw data is extracted from the RT-
PCR machine after the run using Sequence Detection Software SDS (Applied 
Biosystems) and automatically analyzed for DNA copy number prediction using a 
special software called CopyCaller software (Applied Biosystems). 
 
Quantitative real-time polymerase chain reaction (qRT-PCR) 
 
Reverse transcriptase real-time PCR (qRT-PCR) is a very sensitive, specific and 
reproducible method for the detection and the quantification of mRNA [210]. This 
method allows real-time measurement of the PCR product while they accumulate 
during the exponential phase which is directly proportional to the amount of template 
prior to the start of the PCR process (Figure 19A). 
 
There are two main chemistries used for probe labeling and mRNA detection in qRT-
PCR, Taqman probes and SYBR green. Taqman probes only bind single stranded DNA 
molecules (Figure 19B) and is more specific, while SBYR green can bind any double 
stranded DNA molecule (Figure 19C) and hence is less specific. In qRT-PCR, mRNA 
is quantified using either a standard curve or relative quantification. The standard curve 
is usually used for absolute quantification such as for the quantification of viral loads. 
This method uses a series of dilutions of a known standard such as a plasmid for the 
target gene to generate a standard curve and the final mRNA quantity is estimated from 
the linear regression of the standard curve. In relative quantification, the gene 
expression is quantified relative to the reference samples such as normal tissue or 
untreated samples using 2-ΔΔCt method where ΔΔCt = ΔCt (sample) – ΔCt (calibrator), 
and ΔCt is the Ct of the target gene subtracted from the Ct of the housekeeping gene 
[209]. 
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The standard protocol for qRT-PCR starts with the cDNA library synthesis from total 
RNA using commercially available reverse transcriptase cDNA synthesis kits. The 
samples are run in triplicates with the target assay in a qRT-PCR machine. In order to 
quantify the target mRNA, the Ct value is measured using either a standard curve or 
relative quantification with an endogenous control. For our studies (study I, II and IV), 
we have used Taqman probes and relative quantification (2-ΔΔCt) method. 
 
 
 
 
Figure 19. (A) Principle of QRT-PCR (B) Taqman probe (C) SYBR green probe. 
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MATERIALS 
 
This thesis was based on the study of parathyroid tumors. Parathyroid tumor tissues 
were obtained from patients operated for PHPT and immediately snap frozen. The final 
histopathological diagnoses were established according to World Health Organization 
(WHO) [20] criteria and aided by clinical, surgical and pathological findings. Unless 
mentioned otherwise, all parathyroid tumor samples were sporadic as none of the 
patients’ clinical features or family history were suggestive of familial parathyroid 
diseases. Three non-tumorous parathyroid tissues were used as reference samples (N1, 
N2 and N3) in all the four studies. None of the patients from whom normal parathyroid 
tissues obtained had hypercalcemia and/or elevated PTH level. 
All samples were collected with informed consent and approved by the local Research 
Ethics Committee. Table 2 summarizes all the tumor samples used for the studies 
included in this thesis. 
 
Study I  
This study included 21 parathyroid adenoma samples obtained from patients operated 
for primary hyperparathyroidism at Karolinska university hospital during 2005-2009. 
All the 21 adenomas weighed ≥ 4 grams and ranged between 4.07-12.30 grams. They 
were referred to as large parathyroid adenomas (LPTAs) in this study. Eight of the 
patients were males and 13 were females and their ages at diagnosis ranged from 37 to 
84 years. The histopathological classification was based on the WHO criteria [20] 
which identified three cases of atypical adenomas among the 21 LPTAs. 
 
Study II 
In this study, we have investigated two parathyroid tumor samples obtained from two 
patients. The first patient was a 78 year old female with APC mutation-associated 
familial adenomatosis polyposis (FAP) diagnosed and operated on for an ectopic 
parathyroid tumor in Hospital de Santa Maria, Lisbon, Portugal. The excised 
parathyroid tumor measured 21 X 11 X 9 mm and histopathological examination 
established the diagnosis of a single parathyroid adenoma based on WHO criteria. 
The second patient was an 83 year old male with a history of colon polyps, colon 
cancer and Lynch syndrome and was operated for a parathyroid tumor in Karolinska 
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university hospital, Stockholm, Sweden. Similarly, this patient had histopathological 
diagnosis of parathyroid adenoma. The adenoma weighed 7.01 grams. 
Apart from the reference parathyroid samples (N1-3), this study also included two 
atypical parathyroid adenomas used as a negative control for APC immunostaining. 
The control parathyroid samples were also obtained from Karolinska university 
hospital, Stockholm, Sweden. Corresponding blood leukocytes were obtained from 
both patients for mutational analysis of APC. 
 
Study III 
The tumor panel investigated in this study included 9 parathyroid tumors with 
established CDC73/HRPT2 mutations. Three tumors had confirmed diagnosis of 
parathyroid carcinoma (one primary lesion, one from a local recurrence and one from a 
lung metastasis). The remaining tumors included 5 adenomas and one atypical 
adenoma. The atypical adenoma along with one adenoma were obtained from the same 
patient during different time intervals with the atypical tumor being excised last. Only 
one of the patients with parathyroid adenoma was regarded as familial and had FIH. 
The 3 carcinomas and the remaining tumors were obtained from Tokyo women’s 
medical hospital in Japan and Karolinska university hospital in Stockholm, Sweden, 
respectively, during 1994-2006. 
 
Study IV 
A panel of 72 parathyroid tumors including 66 adenomas, 3 atypical adenomas and 3 
carcinomas was investigated in this study. Twenty-one tumors including the 3 atypical 
ones were from the previous study (study I). Six of the adenomas had cystic features. 
Apart from the three carcinomas which were obtained from Tokyo women’s medical 
hospital in Japan and used in study III too, all the other samples were from Karolinska 
university hospital, Stockholm, Sweden. 
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RESULTS AND DISCUSSION 
  Study I: Genetic analysis of large parathyroid adenomas (LPTAs) 
 
LPTAs were defined as the 5% largest sporadic parathyroid adenomas identified among 
the 590 cases operated in our institution during 2005–2009. In this study we asked two 
questions:  What is the genetic profile of parathyroid adenomas with large glandular 
weight? And do large parathyroid adenomas carry malignant potential? To answer 
these questions, we investigated 21 LPTAs weighing ≥ 4 grams. 
 
Correlation of adenoma weight with clinical and biochemical parameters 
LPTAs had a higher relative number of male cases and a more pronounced clinical 
picture reflected by significantly higher S-Ca2+, an observation supporting previous 
reports [211, 212]. 
 
Screening for MEN1 and CDC73 mutations 
Mutational analyses revealed MEN1 mutation in 5 cases and CDC73 mutation in one 
case only, a finding in agreement with previous reports of frequent MEN1, but rare 
CDC73 mutations in parathyroid adenomas [68, 119, 120, 213]. 
 
Staining for MIB-1, APC and Parafibromin 
IHC analyses revealed low MIB1 proliferation index of 1.5% in all the LPTAs favoring 
a benign nature of the tumors. On the other hand, loss of parafibromin staining was 
observed in 10 cases; two of them were also negative for APC. Since loss of APC and 
parafibromin expression are associated with parathyroid carcinoma [214], our 
observations suggest that a subset of LPTAs share molecular characteristics with this 
entity. 
 
CNAs in LPTAs 
Recurrent gross copy number losses of chromosome 1 and 11 and gains of 
chromosome 5 were the most frequently detected CNAs in the LPTAs screened using 
array CGH. Overall, gain of chromosome 5 was the most interesting and unique finding 
as frequent losses on chromosome 1 and 11, but not gain of chromosome 5, are known 
in parathyroid adenomas [150, 152]. Gain of chromosome 5 was reported in 
parathyroid carcinomas [148, 215] and in several other tumors such as low grade renal 
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cell carcinoma, adrenocortical tumors as well as bronchial and gastrointestinal 
carcinoids [216-218]. Unsupervised clustering of the array CGH data clearly identified 
those with gain of chromosome 5 as one group and those with loss of chromosome 11 
as another group, further supporting the that gain of chromosome 5 reflect a distinct 
genetic pathway for a subset of LPTAs that is independent of chromosome 11 loss. 
 
CARD6 as a candidate oncogene 
Taqman DNA copy number analysis validated gain of several candidates genes located 
within minimal overlapping regions on chromosome 5, among them gain of the CARD6 
gene. Over-expression of this gene detected by qRT-PCR further confirmed this 
finding. CARD6 plays an important role in activation of NF-kB signaling, involved in 
proliferation, differentiation and apoptosis [219] and is deregulated in many tumor 
types including parathyroid tumors [220]. The present observations of CARD6 over-
expression as well as copy number gains suggest that evaluation of the protein 
expression could be valuable to further study the possible involvement of this gene in 
parathyroid tumors. 
Finally, we concluded that LPTAs represent a group of patients with pronounced 
parathyroid hyperfunction and associated with specific genomic features. 
  Study II: Molecular characterization of parathyroid tumors from two patients                                                
with hereditary colorectal cancer syndromes 
The primary aim of this study was to investigate possible association between APC 
mutations in hereditary colorectal cancer syndromes and parathyroid tumor 
development. For this purpose, we investigated two parathyroid tumors obtained from 
two patients with familial colon cancers; one with familial adenomatous polyposis 
(FAP) and an established constitutional APC mutation, and second one with Lynch 
syndrome with an underlying germline MLH1 mutation and a non-classified missense 
alteration of the APC gene. 
Histopathological re-examination confirmed the benign nature of both parathyroid 
tumors initially diagnosed as adenomas. To further assess any malignant potential, we 
studied the expression of Ki67, parafibromin and APC as potential molecular markers 
of parathyroid cancer [214, 221] using IHC. Both tumors had low MIB-1 proliferation 
index, negative parafibromin and strongly positive APC staining. Furthermore, while 
both patients carried constitutional APC mutations, no somatic APC mutation could be 
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detected.  To further investigate other possible alterations of the APC gene, we 
analyzed APC gene copy number and promoter methylation using qPCR and bisulfite 
Pyrosequencing, respectively. Both tumors were diploid for APC. While promoter APC 
1B was unmethylated in both tumors, promoter APC 1A was hypermethylated. 
Hypermethylation of the APC 1A promoter has been previously reported in parathyroid 
adenomas and carcinomas [194, 222]. However, this did not seem to affect the 
expression of APC as it was not altered when determined by qRT-PCR. This is possibly 
due to unmethylated transcriptionally active APC 1B promoter, a finding in agreement 
with previous studies [194, 223]. In addition, global methylation level represented by 
LINE-1 analysis did not show any alterations compared to reference parathyroid 
samples. 
The findings in this study supported the benign nature of the parathyroid tumors and 
did not suggest a role for deregulated APC in parathyroid tumors from these two 
patients. 
   Study III: Characterization of CDC73/HRPT2-mutated parathyroid tumors 
 
In this study we aimed to characterize the genetic profile of CDC73/HRPT2 mutated 
parathyroid tumors as well as to investigate possible mechanisms of the CDC73 gene 
inactivation. To accomplish that, we investigated 9 parathyroid tumors (3 carcinomas, 5 
adenomas and one atypical adenoma) with established CDC73 gene mutations for 
CDC73-specific as well as genome-wide alterations. 
 
Screening for CDC73 mutations 
Bi-allelic mutations were detected in 3 tumors and the remaining tumors had 
monoallelic mutations. In 7 tumors the CDC73 mutations were predicted to 
prematurely truncate parafibromin. For the remaining two tumors the mutations were 
predicted to involve the first intron sequence and the first nucleotide of the consensus 
donor splice site of intron 1. 
 
DNA copy number analysis of CDC73 gene using qPCR 
DNA copy number analysis displayed only one copy of the CDC73 gene in 3 of the 
adenomas, which, in previous studies, also exhibited loss of parafibromin expression 
using Western blot and IHC [213] and hence representing the second hit. On the other 
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hand, all the carcinomas were diploid or presented with copy number gain of CDC73 
gene. These results might suggest that parathyroid tumors can develop malignant 
features even with one remaining functional copy of CDC73. 
Global and CDC73 promoter methylation analyses 
All the tumors were unmethylated at the CDC73 promoter, a finding in line with a 
previous report [191]. On the global level, all the tumors were methylated and no global 
hypomethylation could be detected. These findings suggest that promoter methylation 
is an unlikely mechanism of CDC73 gene inactivation and CDC73 mutation itself does 
not induce alterations in global methylation assessed by LINE-1 analysis. 
 
Array-CGH profile in the CDC73-mutated parathyroid tumors 
The a-CGH profiles of the carcinomas and the adenomas were significantly different 
and further confirmed using unsupervised clustering analysis where the carcinomas and 
the adenomas fell into two different clusters. The carcinomas displayed gross deletions 
of 1p, entire chromosome 13 deletions and gain of chromosome 20, with absence of 
any significant CNAs on chromosome 11. These findings are generally similar to 
previously published studies using conventional CGH [148, 215] and possibly reflect 
the aggressive clinical behavior and could correlate with the malignant nature of these 
tumors. On the other hand, and in contrast to previous CGH studies [148, 149, 152, 
154], the adenomas displayed small extent of CNAs with the absence of any significant 
CNAs on chromosome 1 and 11. These results are interesting and support the 
hypothesis that CDC73 gene mutations possibly direct the parathyroid adenomas 
towards a different genetic pathway. 
 
Genome-wide and CDC73 locus LOH analysis using SNP array 
The carcinomas displayed more frequent LOH events than the adenomas with 
chromosome 1 being the most commonly affected in both tumor types. Previous studies 
reported frequent losses on chromosome 1p in parathyroid tumors regardless of the 
CDC73 mutational status and for which no candidate genes have been found [224, 
225]. Furthermore, LOH at the CDC73 locus was only detected in two tumors, one of 
which also displayed copy number loss by TaqMan copy number analysis.  
Our results suggest that CDC73 mutations drive parathyroid tumors into a partly 
distinct cytogenetic pathway different from unselected parathyroid tumors. 
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  Study IV: DNA methylation profiling in parathyroid tumors  
 
Here, we wanted to study the promoter methylation status of several candidate genes 
and see whether aberrant promoter methylation of these genes are involved in 
parathyroid tumorigenesis. For this purpose, we have determined gene-specific 
promoter methylation status of 10 candidate genes including APC (promoter 1A, and 
1B), β-catenin (CTNNB1), CASR, CDC73/HRPT2, MEN1, P16 (CDKN2A), PAX1, 
RASSF1A, SFRP1, and VDR; as well as global methylation level (LINE-1) in 66 
parathyroid adenomas, 3 atypical adenomas and 3 parathyroid carcinomas using 
bisulfite Pyrosequencing. 
 
Gene-specific methylation analysis in parathyroid adenomas and atypical adenomas 
We detected frequent hypermethylation of APC 1A, RASSF1A and β-catenin promoters 
in the adenomas. Frequent hypermethylation of APC 1A and RASSF1A are in line with 
previous studies [194, 195]. The majority of hypermethylated adenomas had reduced 
mRNA expression of the same gene. This association suggests a silencing effect by 
methylation on these genes. None of the other genes had altered methylation status. 
Promoter hypermethylation was detected in only one atypical adenoma for APC 1A. 
 
Gene-specific methylation analysis in parathyroid carcinomas 
Interestingly, all the 3 carcinomas were hypermethylated for RASSF1A and SFRP1, but 
only one was hypermethylated at the APC 1A promoter and none for β-catenin. 
Hypermethylation of APC 1A and RASSF1A have been reported in many other tumors 
such as colorectal [226] and head and neck cancers [227]. Hypermethylation of SFRP1 
has been reported in parathyroid tumors [195] as well as in other tumors such as 
colorectal [228], head and neck [229] and as an independent poor prognostic feature in 
breast cancers [230]. SFRP1 is a potent antagonist of the Wnt signaling pathway and 
hypermethylation of this gene without hypermethylation of β-catenin, might suggests a 
constitutive activation of the canonical Wnt/β-catenin signaling in this subgroup. 
 
Global methylation analysis using LINE-1 
Regardless of tumor type, estimation of LINE-1 methylation density did not reveal any 
change in the global methylation status, a finding in line with our previous studies [194, 
231]. 
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Correlation of the methylation profile to the MEN1 and CDC73/HRPT2 mutational 
status 
Tumors with known MEN1 (5 tumors) or CDC73 mutations (8 tumors) had similar 
methylation profiles suggesting that the mutational status of these two genes is unlikely 
to direct the tumors toward a different methylation profile. 
 
Correlation between clinical/biochemical parameters and gene-specific methylation 
The methylation status of APC 1A was significantly correlated with adenoma weight  
(r = 0.306, P = 0.019). This finding suggests that large parathyroid adenomas could 
have a different DNA methylation pattern in addition to previously reported specific 
genetic profile linked to adenoma size [232]. Furthermore, a statistically significant 
correlation was observed between the methylation status of RASSF1A and with both of 
APC 1A and β-catenin. 
 
These findings support our previous study [194] and reinforce the role of aberrant 
hypermethylation of APC, RASSF1A and β-catenin in the tumorigenesis of a subgroup 
of parathyroid adenomas. It also motivates further studies into the role of aberrant 
methylation of SFRP1 in parathyroid carcinoma development and its role as a potential 
epigenetic marker. 
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CONCLUSIONS 
 
• Large parathyroid adenomas may constitute a subset of parathyroid lesions 
associated with pronounced PHPT features and specific genomic aberrations. 
 
• Large parathyroid adenomas are associated with significantly higher serum 
calcium and therefore more pronounced clinical features. 
 
• The frequency of MEN1 and CDC73 mutations in large parathyroid adenomas 
is similar to those reported for parathyroid adenomas of smaller glandular 
weights. 
 
• CARD6 gene could have oncogenic potential and may play a role on the 
development of a subset of large parathyroid tumors. 
 
• APC gene is unlikely to be involved in parathyroid tumors development in 
patients with APC-mutated associated familial colorectal cancers. 
 
• CDC73 mutations direct parathyroid adenomas in a different genetic pathway 
from those adenomas without established CDC73 mutations. 
 
• Aberrant promoter methylation is an operational mechanism in parathyroid 
tumorigenesis. 
 
• Methylation of APC A1, β-catenin and RASSF1A promoters are deregulated in 
parathyroid tumors and could trigger potential therapeutic targets in the future. 
 
• SFRP1 is a potential epigenetic marker for parathyroid carcinomas and can be 
of important diagnostic aid along with already established molecular markers.  
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